Events & Press Releases
EMMAC and University of Insubria to present abstract at IACM 10th Conference on Cannabinoid in Medicine
31 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, announces that the manuscript, "Immunomodulatory Effect of Cannabidiol: Relevance in Multiple Sclerosis" has been selected for
£15 million raised via successful issue of convertible notes
16 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that it has raised £15 million via an issue of Convertible Loan
Expansion of Research Programme with Imperial College London
10 September 2019, London. EMMAC, the leading European independent medical cannabis company, is pleased to announce an expansion of its research collaboration with Imperial College London. The new research
Research collaboration with University of Insubria
London, 6 August 2019: EMMAC, the leading European independent medical cannabis company, is pleased to announce a collaboration with the Center of Research in Medical Pharmacology at the Italian
EMMAC acquires 100% of Terra Verde
16 July 2019, London. EMMAC Life Sciences Ltd, the leading European independent medical cannabis and wellness company, is pleased to announce that it has acquired 100% of Terra Verde,
Agreement with Farmalabor gives EMMAC immediate access to Italy, Europe’s second-largest Medical Cannabis Market
9 July 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce that it has formed a 50/50 joint venture company, Fontana S.R.L.
EMMAC and Imperial College London manuscript to be published in peer-reviewed Cannabis and Cannabinoid Research Journal
4 July 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that the manuscript, "A comprehensive patient and public involvement programme evaluating perception of cannabis-derived
Rokshaw’s pharmacy Medican registered with General Pharmaceutical Council. Rokshaw now able to deliver medical cannabis direct to Patients across the UK
London, 3 July 2019: EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce its wholly owned subsidiary, Rokshaw Limited (“Rokshaw”), a leading UK EU-GMP
EMMAC to partner with Hyris Ltd to develop Unique Real-Time Phyto-Cannabinoid Rich technology for the specific identification of proprietary cultivars of Cannabis subsp
London, 24 June 2019: EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company, to develop a comprehensive
EMMAC commences construction of planned EU-GMP facility in Malta
18 June 2019, London. EMMAC, the European independent medical cannabis company, is pleased to announce that construction has started on its planned EU-GMP facility in Malta. This follows the
EMMAC announces acquisition of French wellness company, GreenLeaf
Immediate access to French wellness market and established portfolio of hemp-based wellness products 11 June 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased
EMMAC presents to Scientific Committee (CSST) in Paris on Company’s advancement of scientific research into the therapeutic benefits of Medical Cannabis
16 May 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that on Wednesday 15th May, the Company presented to the French Scientific Committee (CSST),
EMMAC to import cannabis products into Germany; supply agreement with CC Pharma
14 May 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that it has entered the German medical cannabis market through the incorporation of About
Acquisition of Rokshaw, a leading UK Specials manufacturer
Immediate access to UK medical cannabis market 9 April 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce completion of the acquisition
Medalchemy, EMMAC’s Spanish GMP certified laboratory, secures approval to import medical cannabis for scientific research
19 March 2019, London: EMMAC, the European independent medical cannabis company, is pleased to announce that Medalchemy, EMMAC’s fully-licensed GMP certified laboratory in Alicante, Spain, has secured approval from
£11 million raised via successful Private Placing
‘Oversubscribed placing with institutional investment from across Europe, North America, Asia and Australia’ 8 March 2019, London. EMMAC Life Sciences Limited, the European independent medical cannabis company, is pleased
EMMAC to present preliminary work on clinical trial design at 5th International Emerald Conference
EMMAC is pleased to announce that the Company will be presenting collaborative work with Imperial College at the 5th International Emerald Conference in San Diego on the 28th of February.
EMMAC Announces Turnkey GMP Facility in Malta to be Group Import and Distribution Hub
EMMAC granted a Letter of Intent under terms of the Production of Cannabis for Medicinal Use Act 2018 EMMAC, the European independent medical cannabis company, is pleased to announce
Announcing the acquisition of leading Swiss wellness CBD company Blossom
Emmac Life Sciences (“EMMAC” or the “Company”) is pleased to announce the acquisition of Blossom, a market-leading Swiss wellness CBD company. The acquisition provides EMMAC with a revenue-making portfolio
Acquisition of a majority interest in Medalchemy, a GMP certified laboratory, in Alicante Spain
Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to import, research, manufacture and export medical cannabis.
Board and Leadership Appointments
Dr Barbara Pacchetti as Chief Scientific Officer and Dr Mikael Sodergren as Research Director Recognised scientific pioneers to drive research and innovation to shape the global future of medicinal
Research collaboration with Imperial College London
A pre-clinical and clinical research programme to investigate cannabis-based medicinal products aimed to directly benefit patients. EMMAC, the European independent medical cannabis company, is pleased to announce a research